If we want Cytodyn to have the ability to conduct trials and develop the full potential of leronlimab, additional shares need to be authorized for the company to have the necessary resources.

The alternatives are licensing deals with big pharma on their terms or a sellout at a fraction of the price we deserve.

IMO